alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 3,526–3,550 of 3,821 studies published 2025 (page 142 of 153) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

HSPA13 gene and microRNA-155: relationship between Down syndrome and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Dementia & neuropsychologia 2025-09-05

Gene dysregulation in trisomy 21 can cause disorders of genes that are members of the heat-shock proteins (HSPs) family and contribute to the early onset of Alzheimer's disease (AD) in Down syndrome (DS). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Nexus Between Exposure to Natural Outdoor Environments and Cognitive Competence among Older Adults in China

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Annals of the American Association of Geographers 2025-03-26

With a rapidly aging population and an increasing number of older people with cognitive impairment, a multitude of social problems could arise. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Tipping the PARylation scale: Dysregulation of PAR signaling in Huntington and neurodegenerative diseases

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Journal of Huntington s Disease 2025-09-04

Poly(ADP-ribosyl)ation (PARylation), a crucial post-translational modification, is catalyzed by ADP-ribosyltransferases (ARTs) and has significant implications in various cellular processes, including DNA damage response, cell signaling, and immune processes. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

T cell drives microglia specific metabolic plasticity and neurodegeneration in Alzheimer disease 4098

✓ Peer-reviewed alzhub usefulness score 31 out of 100. The Journal of Immunology 2025-11-01

Of note, using large-scale transcriptome and chromatin profiling, we show that T cell shape microglia-specific metabolic plasticity in both genetic and epigenetic resolution. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

rs140926439 Variant in the Fibronectin FN1 Gene Lowers Risk of Alzheimer Disease in APOEε4 Carriers in the UK Biobank Cohort

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Alzheimer Disease & Associated Disorders 2025-10-30

When rs140926439 was absent, 0.10% of APOEε2/3 carriers had AD, while 0.43% of APOEε4 carriers or homozygotes had AD. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada

✓ Peer-reviewed alzhub usefulness score 31 out of 100. International Journal of Science and Research Archive 2025-10-31

Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). 5 key findings →

Design: narrative review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada

✓ Peer-reviewed alzhub usefulness score 31 out of 100. International Journal of Science and Research Archive 2025-10-31

Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). 5 key findings →

Design: narrative review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Enhanced Deep Learning Framework for Precise MRI ‐Based Alzheimer's Disease Stage Classification

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Computational Intelligence 2025-08-01

Alzheimer's disease (AD) diagnosis using MRI scans must be very accurate since the subtle differences throughout the course of the disease are difficult to identify. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Perspectives of Former Caregivers of Black Older Adults Living With Dementia on Advance Care Planning

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Journal of Gerontological Nursing 2025-04-24

Future research should leverage perspectives of former caregivers to assist with improving outcomes for Black caregivers, thereby promoting health equity. [ Journal of Gerontological Nursing, 51 (6), 30–37.] 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Leveraging Explainable AI for Dementia Classification: A Machine Learning Approach

✓ Peer-reviewed alzhub usefulness score 31 out of 100. International Journal of Applied Sciences & Development 2025-01-29

In last two decades the growing life expectancy has spiralled the prevalence of neurogenerative disorder such as Dementia among elderly population posing a significant challenge to mental health globally. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Conversion to Mild Cognitive Impairment and Alzheimer’s Disease Dementia Related to Apathy, APOE Genotype and Antidepressant Use

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Journal of Geriatric Psychiatry and Neurology 2025-04-14

Our findings support apathy and APOE ε4 as robust predictors of conversion to MCI and ADD, and demonstrate novel associations between antidepressant use and conversion. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cryo‐EM structures of amyloid β filaments from cotton wool plaques in Alzheimer disease caused by the PSEN1 V261I and A431E mutations

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Alzheimer s & Dementia 2025-12-01

CWPs consist predominantly of two novel arrangements of type I Aβ filaments, and we have designated them as type Ic and type Id Aβ filaments. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed